Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biomet 3Q Loss Widens On Charges; Sales Grow 5%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 04:51pm CET

("Biomet 3Q Loss Widens On Charges; Sales Grow 5%," at 7:03 a.m. EDT, misstated the hip sales increase in the sixth paragraph. The correct version follows:)

Biomet Inc.'s fiscal third-quarter loss widened on merger-related costs as strong sales for sports medicine, extremities and trauma helped drive the orthopedic medical-device maker's top-line growth.

Though privately held, Biomet's results are closely watched because the company reports earlier than larger competitors--such as Zimmer Holdings Inc. (>> Zimmer Holdings, Inc.), Stryker Corp. (SYK) and Johnson & Johnson (>> Johnson & Johnson)--and could foreshadow industry trends.

Biomet has seen its losses widen in recent quarters, weighed down by charges related to its $11.4 billion buyout in 2007 by a private-equity consortium including affiliates from The Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG. Sales have also been weak as patients, worried about out-of-pocket costs or long absences from work to recover, opt to defer hip and knee-replacement procedures. Biomet has said it is unclear when demand will come back.

For the quarter ended Feb. 29, Biomet reported a loss of $16.5 million, compared with a loss of $11.6 million a year earlier. Excluding merger and other special items, adjusted earnings fell to $55.1 million from $63.8 million. Sales jumped 4.5% to $708.9 million.

Gross margin slipped to 69% from 69.3%.

The company, which distributes products in about 90 countries, said worldwide hip sales increased 6%, while worldwide knee sales grew 4%. Sales for sports medicine, extremities and trauma were up 16%, while the spine and bone healing segment saw a 5% drop.

U.S. sales grew 5% while Europe sales rose 2.1%. International sales, which include Canada, South America, Mexico and the Asia-Pacific region, jumped 7.2%.

Last week, Biomet made a binding offer to acquire the global trauma business of Johnson & Johnson's DePuy Orthopaedics Inc. for about $280 million in cash, a deal the company said would greatly expand its sports, extremities and trauma business. Biomet also recently agreed to pay $23 million in penalties to settle U.S. allegations that it bribed doctors in Brazil, China and other countries over a period of years.

--By Anne Pallivathuckal and Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stocks mentioned in the article : Zimmer Holdings, Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
01/15 ZIMMER BIOMET HOLDINGS INC : ZBH INVESTOR DEADLINE NOTICE: Lundin Law PC Announc..
01/14 DEADLINE (ZBH) ALERT : Johnson & Weaver, LLP Reminds Investors of Class Action A..
01/13 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
01/13 JANUARY 31 DEADLINE ALERT : Law Offices of Howard G. Smith Reminds Zimmer Biomet..
01/13 ZIMMER BIOMET HOLDINGS INC : SHAREHOLDER NOTICE: Lundin Law PC Announces Securit..
01/13 ZBH The Law Offices of Vincent Wong Notifies Investors of a Class Action Invo..
01/13 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
01/12 ZIMMER BIOMET HOLDINGS INC. : Agrees to Pay $17.4 Million to Resolve Foreign Cor..
01/11 ZIMMER BIOMET HOLDINGS INC : Lundin Law PC Announces Securities Class Action Law..
01/10 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
06:24p ESSILOR INTL : Luxottica's merger helps Del Vecchio manage family risks
05:27pDJLUXOTTICA : Another Big Splash by Italy's Eyewear King
02:39pDJESSILOR INTL : Luxottica to Merge, Creating $49 Billion Company -- 4th Update
01:11pDJESSILOR INTL : Luxottica to Merge, Creating $49 Billion Company -- 3rd Update
01:07pDJESSILOR INTL : Luxottica to Merge, Creating $49 Billion Company -- 3rd Update
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
01/12 Zimmer Biomet resolves FCPA issues with DOJ and SEC, agrees to pay $30.5M
01/11 Medtech Mergers And Acquisitions Regresses To The Mean In 2016
01/11 Zimmer Biomet (ZBH) presents at 35th Annual J.P. Morgan Healthcare Conference
01/10 Zimmer Biomet 2016 top line above guidance; shares ahead 3% premarket
2016 Zimmer Biomet declares $0.24 dividend
Advertisement
Financials ($)
Sales 2016 7 646 M
EBIT 2016 2 388 M
Net income 2016 457 M
Debt 2016 10 627 M
Yield 2016 0,81%
P/E ratio 2016 51,80
P/E ratio 2017 18,84
EV / Sales 2016 4,41x
EV / Sales 2017 4,10x
Capitalization 23 075 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 130 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Robin T. Barney Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..11.63%23 075
MEDTRONIC PLC5.42%103 102
BAXTER INTERNATIONAL I..4.76%25 265
C R BARD INC4.23%17 218
HOYA CORPORATION-0.12%16 728
TERUMO CORP0.00%14 342
More Results